162 related articles for article (PubMed ID: 34597305)
1. Cytochrome P450-2D6: A novel biomarker in liver cancer health disparity.
Khamis ZI; Pang X; Cui Z; Sang QA; Zhang J
PLoS One; 2021; 16(10):e0257072. PubMed ID: 34597305
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism of hepatocyte nuclear factor-4alpha influences human cytochrome P450 2D6 activity.
Lee SS; Cha EY; Jung HJ; Shon JH; Kim EY; Yeo CW; Shin JG
Hepatology; 2008 Aug; 48(2):635-45. PubMed ID: 18666237
[TBL] [Abstract][Full Text] [Related]
3. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers.
Agúndez JA; Olivera M; Ladero JM; Rodriguez-Lescure A; Ledesma MC; Diaz-Rubio M; Meyer UA; Benítez J
Pharmacogenetics; 1996 Dec; 6(6):501-12. PubMed ID: 9014199
[TBL] [Abstract][Full Text] [Related]
4. Insights into the etiology-associated gene regulatory networks in hepatocellular carcinoma from The Cancer Genome Atlas.
Seshachalam VP; Sekar K; Hui KM
J Gastroenterol Hepatol; 2018 Dec; 33(12):2037-2047. PubMed ID: 29672926
[TBL] [Abstract][Full Text] [Related]
5. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis.
Shen S; Kong J; Qiu Y; Yang X; Wang W; Yan L
J Cell Biochem; 2019 Jun; 120(6):10069-10081. PubMed ID: 30525236
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
[TBL] [Abstract][Full Text] [Related]
7. Use of proteomics to identify mechanisms of hepatocellular carcinoma with the CYP2D6*10 polymorphism and identification of ANGPTL6 as a new diagnostic and prognostic biomarker.
Hu G; Gao F; Wang G; Fang Y; Guo Y; Zhou J; Gu Y; Zhang C; Gao N; Wen Q; Qiao H
J Transl Med; 2021 Aug; 19(1):359. PubMed ID: 34412629
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma.
Shi L; Shang X; Nie K; Lin Z; Zheng M; Wang M; Yuan H; Zhu Z
J Clin Pathol; 2021 Aug; 74(8):504-512. PubMed ID: 33004423
[TBL] [Abstract][Full Text] [Related]
9. Uncovering the potential differentially expressed miRNAs as diagnostic biomarkers for hepatocellular carcinoma based on machine learning in The Cancer Genome Atlas database.
Zhao X; Dou J; Cao J; Wang Y; Gao Q; Zeng Q; Liu W; Liu B; Cui Z; Teng L; Zhang J; Zhao C
Oncol Rep; 2020 Jun; 43(6):1771-1784. PubMed ID: 32236623
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
11. Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.
He ZX; Chen XW; Zhou ZW; Zhou SF
Drug Metab Rev; 2015; 47(4):470-519. PubMed ID: 26574146
[TBL] [Abstract][Full Text] [Related]
12. Nrf2 Regulates the Expression of
Siswanto FM; Handayani MDN; Firmasyah RD; Oguro A; Imaoka S
Curr Drug Metab; 2023; 24(9):667-681. PubMed ID: 37916628
[TBL] [Abstract][Full Text] [Related]
13. Potential targets and molecular mechanism of miR-331-3p in hepatocellular carcinoma identified by weighted gene coexpression network analysis.
Chi Q; Geng X; Xu K; Wang C; Zhao H
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32537629
[TBL] [Abstract][Full Text] [Related]
14. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis.
Lu M; Kong X; Wang H; Huang G; Ye C; He Z
Oncotarget; 2017 Jan; 8(5):8775-8784. PubMed ID: 28060739
[TBL] [Abstract][Full Text] [Related]
15. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer.
Silvestri L; Sonzogni L; De Silvestri A; Gritti C; Foti L; Zavaglia C; Leveri M; Cividini A; Mondelli MU; Civardi E; Silini EM
Int J Cancer; 2003 Apr; 104(3):310-7. PubMed ID: 12569554
[TBL] [Abstract][Full Text] [Related]
16. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.
McConnachie L; Bodor M; Kowdley K; Levy A; Tung B; Thummel K; Phillips B; Bajpai M; Chi V; Esmay JD; Shen DD; Ho RJ
Clin Pharmacol Ther; 2004 Apr; 75(4):282-97. PubMed ID: 15060507
[TBL] [Abstract][Full Text] [Related]
17. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
[TBL] [Abstract][Full Text] [Related]
18. Five lncRNAs associated with the survival of hepatocellular carcinoma: a comprehensive study based on WGCNA and competing endogenous RNA network.
Liu DH; Wang SL; Hua Y; Shi GD; Qiao JH; Wei H
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7621-7633. PubMed ID: 32744688
[TBL] [Abstract][Full Text] [Related]
19. Results and challenges of Cytochrome P450 2D6 (CYP2D6) testing in an ethnically diverse South Florida population.
Salyakina D; Roy S; Wang W; Oliva M; Akhouri R; Sotto I; Mulas N; Solano R; Fernández JR; Sanchez S; Shamshad U; Perlyn C; McCafferty-Fernandez J
Mol Genet Genomic Med; 2019 Sep; 7(9):e922. PubMed ID: 31389673
[TBL] [Abstract][Full Text] [Related]
20. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
